ONL Therapeutics is a pioneering clinical-stage biopharmaceutical company dedicated to protecting and improving vision for patients with retinal diseases. The company is advancing breakthrough therapies aimed at preventing the death of retinal cells, a key driver of vision loss and blindness, by targeting the Fas pathway—a root cause of cell death in the retina. As the first company to focus on preventing Fas-mediated retinal cell death, ONL is leading the way in developing innovative, first-in-class treatments for serious eye conditions. Their lead candidate, ONL1204, is in clinical development to treat retinal detachment, geographic atrophy in age-related macular degeneration, and open-angle glaucoma.